Scientific publications

November 2021
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
SITC Poster
June 2021
Gemcitabine and nab-Paclitaxel ± Nivolumab ± CD40 Agonistic Monoclonal Antibody Sotigalimab (APX005M) in Participants with Untreated Metastatic Pancreatic Adenocarcinoma: Phase 2 Final Results
ASCO Poster
December 2020
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors
ISPNO Presentation
February 2020
A Phase II Trial with a Safety Lead-in to Evaluate the Addition of APX005M, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Patients with Advanced Sarcoma
ASCO SITC Poster
September 2019
Intratumoral CD40 Agonist (APX005M) in Combination with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in CPI Treatment Naïve Metastatic Melanoma
CICON Poster
April 2019
Phase 1b/2 Study of CD40 Agonistic Antibody APX005M in Combination with Nivolumab (Nivo) in Subjects with Metastatic Melanoma (M) and Subjects with Non-Small Cell Lung Cancer (NSCLC)
AACR Poster
March 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients
AACR Presentation
January 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients
ASCO GI Abstract
June 2018
Phase I/II Dose Escalation and Expansion Study of Image Guided Intratumoral APX005M in Combination with Systemic Pembrolizumab in Treatment Naïve Metastatic Melanoma Patients
ASCO Poster
November 2017
A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients
SITC Poster